找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Disease Recurrence After Liver Transplantation; Natural History, Tre Paul J. Thuluvath Book 2016 Springer Science+Business Media New York 2

[復(fù)制鏈接]
樓主: otitis-externa
21#
發(fā)表于 2025-3-25 04:28:42 | 只看該作者
Cholangiocarcinoma,modal therapies including neoadjuvant chemotherapy and/or radiation, and surgical exploration followed by LTX offer patient survival rates comparable to LTX done for other liver disease etiologies in a select group of patients. At this time, LTX for cholangiocarcinoma should be performed using stric
22#
發(fā)表于 2025-3-25 07:45:25 | 只看該作者
Recurrent Non-hepatic and De Novo Malignancies After Liver Transplantation,rson-years calculated by adding survival of each patient) are compared with epidemiological data for each cancer type. This method provides the precise incidence of cancer post-LTx compared to general population. Rates of malignancy increase in proportion to age at transplant and length of follow-up
23#
發(fā)表于 2025-3-25 13:18:16 | 只看該作者
24#
發(fā)表于 2025-3-25 17:31:15 | 只看該作者
25#
發(fā)表于 2025-3-25 22:13:09 | 只看該作者
Ivica Milevski,Ekaterina Ivanovaotentially reverses the consequences and complications of the initial abnormalities depending on the severity of the complications, reversibility, and time interval between the diagnosis of the problem and replacement of the liver.
26#
發(fā)表于 2025-3-26 00:09:16 | 只看該作者
27#
發(fā)表于 2025-3-26 04:47:32 | 只看該作者
28#
發(fā)表于 2025-3-26 11:05:50 | 只看該作者
vered.As there is a high incidence of disease recurrence after liver transplantation, this volume is designed around the need for a reference text dealing exclusively with this problem. The book places special emphasis on pre- and post-transplant predictors of recurrence, severity assessment, prophy
29#
發(fā)表于 2025-3-26 14:10:09 | 只看該作者
30#
發(fā)表于 2025-3-26 18:50:32 | 只看該作者
Ivica Milevski,Ekaterina Ivanovaion resulting in cardiovascular events—which is considered today the leading cause of death following liver transplantation in NASH recipients, surpassed only by sepsis. Patients with NASH cirrhosis should be carefully evaluated and selected for liver transplantation, and metabolic risk factors should be treated aggressively.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 21:02
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
保靖县| 长丰县| 湘阴县| 来凤县| 宜都市| 拉萨市| 临沭县| 宿迁市| 遵义市| 遂宁市| 开阳县| 桂林市| 五家渠市| 屏东县| 沂南县| 腾冲县| 泽库县| 昆明市| 噶尔县| 田东县| 河北省| 中超| 吉林省| 马公市| 内乡县| 黔东| 光山县| 大埔区| 巢湖市| 石渠县| 孙吴县| 增城市| 雷波县| 健康| 祁门县| 邵阳县| 霍林郭勒市| 巴彦淖尔市| 武乡县| 五大连池市| 仙桃市|